| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.3 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.065 | 0.3 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.3 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.3 |